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ABSTRACT
Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is estimated to 
account for over 44,000 new cases of Kaposi sarcoma annually, with 84% occurring 
in Africa, where the virus is endemic. To date, there is no prophylactic vaccine against 
KSHV. KSHV gpK8.1, gB, and gH/gL glycoproteins, implicated in the virus entry into 
host cells, are attractive vaccine targets for eliciting potent neutralizing antibodies 
(nAbs) against virus infection. We incorporated gpK8.1, gB, or gH/gL on the surface 
of virus-like particles (VLPs) and characterized these VLPs for their composition, 
size, and functionality. To determine which viral glycoprotein(s) elicit the most 
effective serum-nAbs, we immunized BALB/c mice with gpK8.1, gB, or gH/gL VLPs 
individually or in combination. Neutralizing antibody assay revealed that sera from 
mice immunized with the VLPs inhibited KSHV infection of HEK-293 cells in a dose-
dependent manner. As a single immunogen, gpK8.1 VLPs stimulated comparable nAb 
activity to that of UV-inactivated KSHV (UV-KSHV). In contrast, UV-KSHV stimulated 
higher titers of nAb compared to gB (p = 0.0316) or gH/gL (p = 0.0486). Mice 
immunized with the combination of gB and gH/gL VLPs had a better nAb response 
than those immunized with either gB (p = 0.0268), or gH/gL (p = 0.0397) as single 
VLP immunogens. Immunization with any VLP combination stimulated comparable 
nAb activity to UV-KSHV serum. Our data provide the first evidence that KSHV gpK8.1, 
gB, and gH/gL glycoproteins can be incorporated onto the surface of VLPs and used 
as prophylactic vaccine candidates, with potential to prevent KSHV infection.
INTRODUCTION
Kaposi sarcoma-associated herpesvirus (KSHV), 
also known as human herpesvirus-8 (HHV-8), is the 
etiologic agent of Kaposi sarcoma (KS), an endothelial 
cell tumor [1]. KSHV is also associated with primary 
effusion lymphoma and multicentric Castleman disease 
lymphoproliferative disorders [2]. KSHV transmission 
occurs mainly via saliva exchange, sexual contact, and 
rarely, through organ transplantation and blood transfusion 
[3–9]. The seroprevalence of KSHV varies globally, with 
high rates in parts of Africa and South America (30-60%, 
considered to be endemic), intermediate rates in the 
Mediterranean region (4-35%), and low rates in North 
America, Western Europe, and Asia (<10%) [10–13]. KS is 
most frequent in regions with high KSHV seroprevalence, 
such as African and Mediterranean countries [14].
KSHV-associated malignancies predominantly present 
in people with primary and acquired immunodeficiencies, 
including acquired immunodeficiency syndrome (AIDS) and 
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iatrogenic immunosuppression in organ transplant recipients 
[15, 16]. KS is one of the most frequent malignancies seen 
in AIDS patients [17, 18]. It is a major cause of morbidity 
and mortality in adults in sub-Saharan Africa, where the 
prevalence of HIV/AIDS is high, and it is an emerging 
problem for children [19–21]. Despite a significant reduction 
in the incidence of KS since the introduction of highly active 
antiretroviral therapy (HAART), there are still approximately 
44,000 new cases of KS worldwide each year, with 84% 
occurring in Africa [22]. Furthermore, only 50% of patients 
achieve complete resolution of KS lesions with HAART [23]. 
Thus, there is a need for improved preventive and therapeutic 
approaches to KS.
Prophylactic vaccines typically stimulate an 
individual’s humoral immune system to produce neutralizing 
antibodies against the surface glycoprotein(s) mediating the 
infectious agent’s entry [24, 25]. The role of neutralizing 
antibodies in preventing KSHV infection or KSHV-
associated malignancies has not been determined. To date, 
efforts to develop a prophylactic vaccine against KSHV have 
been lacking, with no preclinical or clinical vaccine trial 
reported in the past three decades, despite the AIDS pandemic 
[26]. A KSHV vaccine would be highly beneficial for at-risk 
populations, e.g., those at high risk of HIV infection, people 
living in KSHV-endemic areas, or individuals undergoing 
iatrogenic immunosuppression after organ or stem cell 
transplantation. An effective KSHV vaccine could even 
eradicate the virus and its associated malignancies in areas 
where low seroprevalence rates are reported.
Like all other herpesviruses, KSHV enters 
target cells through a multi-step process that involves 
interactions between multiple viral envelope glycoproteins 
and host cell surface molecules that include attachment 
and fusion receptors [27, 28]. The KSHV envelope 
glycoproteins implicated in virus-cell attachment and 
fusion, and which facilitate viral entry are gpK8.1, gB, 
and gH/gL. Both gpK8.1 and gB are thought to initiate 
viral entry by binding to host cell surface heparan sulfate 
[29, 30]. This leads to conformational changes that allow 
access to specific entry receptors, including integrins and 
ephrin receptors, which facilitate viral uptake into the host 
cells [31]. gB binds to integrin receptors, while gH and gL 
form a non-covalently linked complex that interacts with 
the ephrin receptor EphA2 [32]. Studies have shown that 
the gH/gL complex is indispensable for viral entry, and 
that antibody blockade of gH/gL affects KSHV target cell 
entry without affecting binding [33].
We developed KSHV envelope glycoprotein-
based virus-like particles (VLPs) as prophylactic vaccine 
candidates. VLPs are self-assembling structures composed 
of one or more viral proteins. They can serve as delivery 
systems to present antigens from different types of 
pathogens [34]. The size and structure of VLPs closely 
resembles those of native virus, but they are non-infectious, 
as they lack viral genetic material. These qualities make 
VLPs a highly immunogenic and safe vaccine platform for 
oncogenic viruses such as KSHV [35].
This study demonstrates that targeting viral entry 
as a strategy for prevention of KSHV infection and its 
associated malignancies is feasible. We used the Newcastle 
disease virus (NDV) platform to generate VLPs bearing 
KSHV gpK8.1, gB, or gH/gL envelope glycoproteins. 
We immunized wild-type BALB/c mice and measured 
neutralizing antibody response. Our results confirm that 
KSHV glycoprotein-based VLPs are immunogenic and 
generate a KSHV-specific immunoglobulin G (IgG) 
antibody response in immunized mice. In addition, in vitro 
neutralization assays performed using recombinant KSHV 
tagged with enhanced green fluorescent protein (KSHV-
eGFP) showed that antibodies generated by KSHV 
glycoprotein-based VLP-immunized mice can inhibit 
KSHV infection in vitro.
RESULTS
Construction of chimeric gpK8.1-F, gB-F, gH-F, 
and gL-HN cDNA plasmids, and purification and 
characterization of KSHV VLPs
To generate KSHV gpK8.1 VLPs, we first designed 
and synthesized a chimeric KSHV gpK8.1-F construct 
by fusing the KSHV gpK8.1 ectodomain to the NDV 
fusion protein (F) heptad repeat 2 (HR2), transmembrane 
(TM), and cytoplasmic (CT) domains (Figure 1A). The 
construct was cloned into a mammalian expression vector 
(pCAGGS) and the fidelity of the chimeric gene was 
verified by sequencing.
To demonstrate that chimeric gpK8.1-F is 
functionally expressed on the surface of cells, we 
transfected Chinese hamster ovary (CHO) cells with the 
gpK8.1-F plasmid or relevant controls. Forty-eight hours 
post-transfection, cells were stained with anti-gpK8.1 
mouse monoclonal antibody (mAb), which detects the 
ectodomain of the protein, followed by secondary anti-
mouse antibody conjugated to Alexa Fluor (AF488) 
fluorochrome. Flow cytometry showed that CHO cells 
transfected with the pCAGGS-gpK8.1-F chimera robustly 
expressed gpK8.1 (88% expression), similar to cells 
transfected with pCAGGS-gpK8.1 full-length (WT) (82% 
expression), which served as a positive control (Figure 
1B). Cells transfected with empty pCAGGS vector 
(negative control) did not express gpK8.1.
To assemble and produce gpK8.1 VLPs, equal 
amounts of gpK8.1-F, NDV-matrix (M), and NDV-
nucleocapsid protein (NP) cDNA plasmids were co-
transfected into CHO cells (Figure 1C). The cell 
supernatant containing VLPs was collected every 24h until 
96 h post-transfection. VLPs were purified as previously 
described [25, 36].
To confirm that gpK8.1, NP, and M were 
incorporated into gpK8.1 VLPs, we lysed purified VLPs 
in RIPA buffer and analyzed the lysates for protein 
composition by immunoblot (Figure 2A). As expected, 
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Figure 1: Schematic representation of the construction of chimeric KSHV gpK8.1-F and production of gpK8.1 VLPs. 
A. gpK8.1-F plasmid constructs (not to scale) showing full-length NDV-F (top), full-length/wild-type (WT) gpK8.1 (middle), and chimeric 
gpK8.1-F (bottom). B. Flow cytometric analysis for surface expression of gpK8.1 protein on 106 CHO cells transfected with 1 µg of 
pCAGGS gpK8.1-F chimera, pCAGGS gpK8.1 WT (positive control), and empty pCAGGS vector (negative control) was performed at 
48 h post-transfection. Transfected cells were resuspended in PBS, stained with anti-gpK8.1 mAb, which detects the ectodomain of the 
protein, followed by secondary antibody goat-anti-mouse IgG conjugated to AF488. From left, gpK8.1-F chimeric protein is robustly 
expressed on the surface of CHO cells, similar to WT gpK8.1 (middle panel), and no gpK8.1 protein was detected in CHO cells transfected 
with pCAGGS alone (negative control). C. Illustration of co-transfection of CHO cells with three cDNA plasmids required to make VLPs, 
pCAGGS cDNAs NDV-M, NDV-NP and gpK8.1-F, resulting in release of fully-assembled gpK8.1 VLPs. cDNAs NDV-M and NDV-NP 
have been described (see Materials and Methods).
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Figure 2: Characterization of KSHV gpK8.1 VLPs. A. CHO cells transfected with empty pCAGGS or pCAGGS-NP, or purified 
gpK8.1 VLPs were lysed and analyzed by immunoblot using anti-gpK8.1 mAb and rabbit polyclonal anti-NDV to detect various VLP 
components. Anti-gpK8.1 (top panel) detected gpK8.1 (62-72 KDa) in VLP lysate (lane 4), but not in CHO pCAGGS or CHO NP (negative 
controls, lanes 2-3). Anti-NDV (bottom panel; a gift of Dr. T. Morrison, University of Massachusetts Medical School) detected NP alone in 
lysate from CHO NP (lane 3), and NP and M in gpK8.1 VLPs (lane 4), but not in CHO pCAGGS lysate (negative control, lane 2). B. Silver 
stain was used to visualize VLP purity relative to purified NDV. Arrows indicate viral/VLP components in 5 µl purified NDV diluted 
1:30 (lane 1), and 1 µl and 2.5 µl of purified gpK8.1 VLPs diluted 1:40 (lanes 4-5). Lanes 2 and 3 were loaded with 1 µg and 2 µg BSA, 
respectively for protein quantification. C. Electron microscopy showing structural similarity between KSHV virions and gpK8.1 VLPs. 
Purified VLPs were dialyzed against 1 L TNE buffer to remove residual sucrose, incubated with 3% bovine serum albumin (BSA) in TNE 
for 45 min, and embedded on a grid. 5 µl of the virus/VLP at 1:40 dilution was individually added to the grid for 1 h at room temperature. 
After two final washes, the grids were negatively stained with 12% phosphotungstic acid (pH 7) for 15 sec, air dried for 30 min, and 
examined using a Tecnai transmission electron microscope (FEI). D. Confocal microscopy shows gpK8.1 VLPs binding to lipid rafts on 
HMC-1 cells. Purified gpK8.1 VLPs were incubated with HMC-1 cells for 10 min at room temperature and stained with anti-gpK8.1, 
followed by secondary antibody conjugated with Alexa-Fluor 594 (red) to detect gpK8.1 VLPs, cholera toxin (green) to detect lipid rafts, 
and DAPI (blue) to detect HMC-1 nuclei. The red and green staining shows VLPs bound cell membranes; HMC-1 cells not incubated with 
VLPs did not stain red (negative control, inset). VLPs (red) binding to lipid rafts are not seen in HMC-1 cells not incubated with VLPs 
(negative control, inset).
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anti-gpK8.1 mAb detected gpK8.1 (~60–72 kDa) in 
purified VLPs (top panel, lane 4). No gpK8.1 protein 
was detected in lysates from CHO cells transfected with 
either empty pCAGGS vector or pCAGGS-NP (negative 
controls). Detection with rabbit polyclonal anti-NDV 
recognized NDV-NP in cells transfected with pCAGGS-
NP and both NDV-NP and -M components in purified 
VLPs (bottom panel, lanes 3-4). No NDV components 
were detected in CHO cells transfected with empty 
pCAGGS vector (negative control). Immunoblot of 
gpK8.1 VLPs relative to additional controls (irrelevant 
Epstein-Barr VLPs, purified NDV, lytically induced 
iSLK.219 KSHV-eGFP-expressing cells, purified Epstein-
Barr virus, and iSLK cells) confirmed that KSHV VLPs 
contained only the expected components (Supplementary 
Figure 1).
To assess the purity of gpK8.1 VLPs, we used silver 
stain; NDV lysate served as a positive control, and BSA 
was used for quantification of proteins. Bands of predicted 
sizes were detected for gpK8.1 (60-72 kDa), NDV-NP 
(~50 kDa), and NDV-M (35-45 kDa) (Figure 2B). Electron 
microscopy of gpK8.1 VLPs confirmed that gpK8.1 VLPs 
structurally resembled KSHV (Figure 2C).
To confirm that chimeric gpK8.1-F proteins 
incorporated into VLPs were in the right conformation 
and able to bind cellular surface receptors, purified gpK8.1 
VLPs were incubated with human mast cells 1 (HMC-1) 
susceptible to KSHV infection. Cells incubated with 
VLPs were stained with anti-gpK8.1 mAb conjugated 
with AF-594 (red) to detect gpK8.1 VLPs, cholera toxin 
(green) to detect lipid rafts, and DAPI (blue) to detect 
HMC-1 nuclei (Figure 2D). HMC-1 cells not incubated 
with VLPs were used as negative control (inset). Stained 
cells were analyzed by confocal microscopy as described 
in Materials and Methods, and showed binding of VLPs 
to the lipid rafts in the cell membranes of VLP-incubated 
cells, indicative of functional binding.
Upon successful generation and characterization 
of gpK8.1 VLPs, we used a similar strategy to generate 
KSHV gB and KSHV gH/gL VLPs. To generate KSHV 
gB VLPs, we synthesized a chimeric gB-F construct by 
fusing the KSHV gB ectodomain to the NDV-F HR2, TM, 
and CT domains (Figure 3A). The construct was cloned 
into the pCAGGS expression vector, sequence verified, 
and used to co-transfect CHO cells, together with equal 
amounts of NDV-NP and NDV-M. KSHV gB VLPs were 
purified as previously described [25, 36]. We confirmed 
expression of component proteins gB, NDV-M, and NDV-
NP using immunoblot of purified gB VLPs and relevant 
controls. Due to lack of an effective commercial antibody 
that has been optimized against KSHV gB, we detected 
the gB-F fusion protein using anti-NDV F tail. Anti-F tail 
predominantly detected the cleaved forms of the gB-F 
fusion protein (~75 and ~55 kDa). Anti-NDV detected 
NDV-NP in CHO cells transfected with pCAGGS-NP 
(positive control), and NP and M in gB-F VLPs, but not 
in CHO cells transfected with empty pCAGGS vector 
(negative control) (Figure 3B).
To assess purity, and to confirm detection of the 
various components of the gB VLP, we used silver stain. 
NDV lysate was used as a positive control, and BSA was 
used for quantification of protein. KSHV gB is synthesized 
as a 110-kDa precursor protein which undergoes furin 
cleavage and processing to yield envelope-associated 
disulfide-linked 75- and 55-kDa polypeptides [37]. Bands 
of predicted sizes were detected for uncleaved (~110 
kDa) and furin-cleaved gB (~75 and 55 kDa), NDV-NP 
(~50 kDa), and NDV-M (35-45 kDa) (Figure 3C). To 
confirm that gB-F proteins incorporated on the surface of 
VLPs were functional and bound cell surface receptors, 
we incubated purified gB VLPs with HMC-1 cells and 
performed immunofluorescent confocal microscopy, 
as above. Cells incubated in the presence, but not the 
absence (inset), of gB VLPs showed binding of VLPs (red) 
with lipid rafts in cell membranes (green), indicative of 
functional binding (Figure 3D).
To generate KSHV gH/gL VLPs, we synthesized 
chimeric gH-F and gL-HN constructs by fusing the KSHV 
gH ectodomain to the NDV-F HR2, TM, and CT domains 
(Figure 4A), and the KSHV gL ectodomain to the NDV 
hemagglutinin-neuraminidase protein (NDV-HN) TM 
and CT domains (Figure 4B). The rationale for fusion of 
a type 1 membrane protein (i.e., gH) to NDV-F protein 
and a type 2 membrane protein (i.e., gL) to NDV-HN 
has been described [38]. Synthesized cDNA constructs 
(gH-F and gL-HN) were individually cloned into the 
pCAGGS expression vector, sequence verified, and used 
to co-transfect CHO cells with NDV-NP and -M. VLPs 
were purified as previously described [25, 36]. To confirm 
protein components of purified VLPs we performed 
immunoblot analysis with purified VLPs lysed in RIPA 
buffer (Figure 4C). Due to lack of an effective commercial 
antibody optimized against KSHV gH/gL for immunoblot, 
we detected the gH-F chimeric protein using anti-NDV 
F HR2 domain (top panel). Anti-HR2 detected the gH-F 
component in purified gH/gL VLPs (5 µg and 10 µg), 
but not in CHO cells transfected with empty pCAGGS 
vector, pCAGGS NDV-NP, or wild-type gH or gL, or in 
lysates from lytically induced iSLK.219 KSHV-eGFP-
expressing cells (negative controls). Anti-NDV detected 
NDV-NP and -M on gH/gL VLPs and NP alone in CHO 
cells transfected with pCAGGS-NP (positive control), but 
not in CHO cells transfected with empty pCAGGS vector, 
CHO cells transfected with wild-type gH, gL, or chimeric 
gH-F, or in iSLK.219 lysate (negative controls) (bottom 
panel). Further immunoblot analysis of gH/gL proteins 
using unpurified sera from mice immunized with gH/gL 
VLPs confirmed VLP composition to include gH, gL, NP 
and M (Supplementary Figure 2).
To assess purity of the gH/gL VLPs, and to confirm 
expression of the gH and gL protein components, we used 
silver stain. NDV lysate was used as a positive control, and 
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Figure 3: Construction of KSHV gB-F and characterization of KSHV gB VLPs. A. KSHV gB-F plasmid constructs (not to 
scale) showing full-length NDV-F (top), full-length/wild-type (WT) gB (middle), and chimeric gB-F (bottom). B. CHO cells transfected 
with empty pCAGGS vector or pCAGGS-NP, or purified gB VLPs were lysed and analyzed by immunoblot using polyclonal anti-NDV 
F tail and anti-NDV. Anti-F tail (top panel) detected the cleaved forms of the gB-F fusion protein (~55 and ~75 kDa) in 5 µg and 10 µg 
of purified gB VLPs (lanes 3-4), but not in CHO pCAGGS or CHO NP lysates (negative controls, lanes 1-2). Anti-NDV (bottom panel) 
detected NP alone in CHO NP (positive control, lane 2), and NP and M in gB VLPs (lanes 3-4), but not in CHO pCAGGS (negative control, 
lane 1). C. Silver stain was used to visualize VLP purity relative to purified NDV, and detected uncleaved and cleaved gB-F proteins of 
~110, and 55-75 kDa. Arrows indicate viral/VLP components in 5 µl purified NDV diluted 1:30 (lane 1), and 1 µl purified gB VLPs diluted 
1:40 (lane 4). Lanes 2 and 3 were loaded with 1 µg and 2 µg BSA, respectively for protein quantification. D. Confocal microscopy shows gB 
VLPs binding to surface receptors on HMC-1 cells. Purified gB VLPs were incubated with HMC-1 cells for 10 min at room temperature and 
stained with rabbit polyclonal anti-gB, followed by secondary antibody conjugated with Alexa-Fluor 594 (red) to detect gB VLPs, cholera 
toxin (green) to detect lipid rafts, and DAPI (blue) to detect HMC-1 nuclei. The red and green staining shows VLPs bound cell membranes; 
HMC-1 cells not incubated with VLPs did not stain red (negative control, inset).
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Figure 4: Construction of KSHV gH-F/gL-HN and characterization of KSHV gH/gL VLPs. A. gH-F plasmid constructs 
(not to scale) showing full-length NDV-F (top), full-length/wild-type (WT) gH (middle), and chimeric gH-F (bottom). B. gL-HN plasmid 
constructs (not to scale) showing full-length NDV-HN (top), full-length/WT gL (middle), and chimeric gL-HN (bottom). C. Purified gH/
gL VLPs, CHO cells transfected with pCAGGS, pCAGGS-NP, -gH WT, -gL WT, -gH-F, gL-HN, and lytically induced iSLK KSHV-eGFP 
expressing cells were lysed in RIPA buffer and analyzed by immunoblot with polyclonal anti-NDV F HR2 and anti-NDV. Anti-HR2 
detected gH-F in 5 µg and 10 µg gH/gL VLPs (lanes 9-10) and in CHO gH-F cells (positive control, lane 7), but not other samples (negative 
controls). Anti-NDV (bottom panel) detected NP alone in CHO NP (positive control, lane 3), and NP and M in gB VLPs (lanes 9-10), 
but not in other samples (negative controls). For detection of gL-HN using polyclonal antibody raised from mice immunized with gH/gL 
VLPs see Supplementary Figure 2. D. Silver stain was used to visualize VLP purity relative to purified NDV. Arrows indicate viral/VLP 
components in 5 µl purified NDV diluted 1:30 (lane 1), and 2 µl purified gH/gL VLPs diluted 1:40 (lane 4). Lanes 2 and 3 were loaded with 
1 µg and 2 µg BSA, respectively for protein quantification. E. Confocal microscopy shows gH/gL VLPs binding to surface receptors on 
HMC-1 cells. Purified gH/gL VLPs were incubated with HMC-1 cells for 10 min at room temperature and stained with anti-gH, followed 
by secondary antibody conjugated with Alexa-Fluor 594 (red) to detect gH/gL VLPs, cholera toxin (green) to detect lipid rafts, and DAPI 
(blue) to detect HMC-1 nuclei. The red and green staining shows VLPs bound cell membranes; HMC-1 cells not incubated with VLPs did 
not stain red (negative control, inset).
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BSA (1 µg and 2 µg) was used for quantification of protein. 
Bands of predicted sizes were detected for gH (85 kDa), gL 
(25 kDa), NDV-NP (~50 kDa), and NDV-M (35-45 kDa) 
(Figure 4D). To confirm that the VLPs were functional and 
bound cell surface receptors, we incubated purified gH/gL 
VLPs with HMC-1 cells and performed immunofluorescent 
confocal microscopy, as above. Cells incubated in the 
presence, but not the absence (inset), of gH/gL VLPs showed 
binding of VLPs (red) with lipid rafts in cell membranes 
(green), indicative of functional binding (Figure 4E).
KSHV VLPs stimulate KSHV-specific IgG 
antibody responses in immunized BALB/c mice
To test the ability of individual KSHV envelope 
glycoprotein-based VLPs to stimulate KSHV-specific 
antibody responses, three groups of five female BALB/c 
mice each were immunized intraperitoneally with 10 μg of 
purified gpK8.1, gB, or gH/gL VLPs suspended in 0.5 ml 
of TNE buffer without adjuvants. Two groups of five mice 
each were immunized with TNE buffer alone (negative 
control) or UV-inactivated KSHV (positive control). To 
test additive or synergistic effects of two or more KSHV 
glycoprotein immunogens [39], we also immunized four 
groups of five mice each with two or three individual 
VLPs (gpK8.1 and gB; gpK8.1 and gH/gL; gB and gH/
gL; or gpK8.1, gB, and gH/gL).
The mice were immunized at Day 0 and boosted 
twice, on Days 29 and 54. Mice were tail-vein bled on 
Days 14, 46, and 84, with a terminal bleed on Day 133 
(Figure 5A).
To demonstrate the ability of KSHV VLPs to induce 
KSHV-specific antibody responses, we used ELISA to 
determine the presence of anti-KSHV IgG antibodies in 
sera of immunized mice. Lysate from lytically induced 
iSLK.219 KSHV-eGFP-expressing cells, which express 
all KSHV envelope glycoproteins, served as the binding 
target. Sera from all bleeding time-points were analyzed. 
All VLP-immunized mice generated KSHV-specific 
IgG antibody responses that increased following booster 
immunizations, compared with TNE-immunized mice 
(negative control) (Figure 5B). The increase in KSHV-
specific antibody response peaked by Day 84, after the 
second booster immunization, similarly to UV-inactivated 
KSHV-immunized mice (positive control). The antibody 
responses to the KSHV-envelope glycoprotein-based 
VLPs were long-lived, as the titers were still high even 
after 133 days. A detailed analysis of serum antibody 
responses in individual mice at each time point is provided 
in Supplementary Figure 3.
Antibodies from mice immunized with KSHV 
VLPs neutralize KSHV infection in vitro
To assess the ability of VLP-immunized sera to 
neutralize KSHV infection in vitro, sera collected at Day 
133 were used to conduct KSHV infection neutralization 
assays. HEK-293 cells were used as the host for the 
neutralization assays, as a model of epithelial cells that 
are susceptible to KSHV infection [40]. Cells were 
exposed to KSHV-eGFP purified from lytically induced 
iSLK.219 cells in the absence or presence of sera from 
VLP-immunized animals. The virus titer was determined 
by an infectivity assay, as previously described [25] and as 
briefly outlined in Materials and Methods sections. Known 
KSHV-positive plasma (488HO4), a gift of Dr. Wood, 
University of Nebraska, Lincoln, served as positive control 
and neutralized >80% of KSHV infection at 1:6, 1:9, and 
1:18 dilutions. Sera from mice immunized with TNE (data 
not shown) served as negative control and was used to 
normalize the percent infection. Upon pre-incubation of 60 
μl of KSHV-eGFP with sera from mice immunized with 
KSHV glycoprotein-based VLPs, infection of HEK-293 
cells was reduced with increasing antibody concentration 
(Figure 6). At a 1:18 serum dilution, pooled serum from 
individual mice immunized with a combination of either 
gB-gH/gL, gpK8.1-gB-gH/gL, or gpK8.1-gH/gL VLPs 
showed the best neutralization, inhibiting infection by 
63.5%, 51%, and 54.7% respectively, compared to <50% 
for the mice immunized with single gpK8.1, gB, or gH/
gL VLPs.
Data from three independent experiments at a 1:9 
serum dilution were used to determine the effectiveness 
of each glycoprotein in eliciting neutralizing antibodies 
as a single or combined immunogen(s) (Figure 7). 
Sera from mice immunized with a gpK8.1 VLPs as a 
single immunogen stimulated comparable neutralizing 
antibody activity to UV-inactivated KSHV. In contrast, 
immunization with gB or gH/gL VLPs as single 
immunogens stimulated a less effective neutralizing 
antibody responses compared to UV inactivated-KSHV 
(p = 0.0316, p = 0.0486, respectively). Immunization 
with a combination of gB and gH/gL VLPs had a 
better neutralizing antibody response than either single 
immunogen, gB (p = 0.0119), or gH/gL (p = 0.0133). 
Importantly, immunization with any combination 
containing gpK8.1 VLPs (gpK8.1-gB, gpK8.1-gH/gL, and 
gpK8.1-gB-gH/gL) stimulated comparable neutralizing 
antibody activity to UV-inactivated KSHV. Our findings 
confirm that immunization with a combination of 
immunogens has an additive effect on immunogenicity 
and neutralizing antibody response.
DISCUSSION
KS is a significant cause of morbidity and mortality 
in sub-Saharan Africa. Primary prevention by vaccination 
against KSHV could play an important role in limiting 
virus shedding and transmission, thus reducing the 
burden of KS in KSHV-endemic areas. To the best of our 
knowledge, this is the first study to generate VLPs using 
KSHV glycoproteins gpK8.1, gB, or gH/gL as target 
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immunogens to serve as prophylactic vaccine candidates 
for prevention of KSHV infection.
We showed that co-transfection of CHO cells 
with chimeric KSHV envelope glycoproteins and NDV 
structural proteins leads to successful production of 
gpK8.1, gB, and gH/gL VLPs. These VLPs resemble 
native virus and bind the KSHV-susceptible HMC-1 cell 
line, demonstrating that the conformation of the viral 
glycoproteins is conserved and functional.
Importantly, immunization of female wild-type 
BALB/c mice with KSHV glycoprotein-based VLPs 
singly or in combination induced humoral immune 
responses, resulting in moderately high titers of serum 
antibodies relative to UV-inactivated KSHV. Antibody 
Figure 5: Immunization and generation of specific anti-KSHV IgG antibody responses in BALB/c mice. A. Immunization 
and bleeding schedule of 6–8-week-old female BALB/c mice. A total of 9 groups of five BALB/c mice each were immunized with 10 µg 
of purified gpK8.1, gB, or gH/gL VLPs, or a combination of gpK8.1 and gB; gpK8.1 and gH/gL; gB and gH/gL; or gpK8.1, gB, and gH/
gL VLPs. Two groups were immunized with either 10 µg of purified UV-inactivated KSHV (positive control) in TNE buffer, or TNE 
buffer alone (negative control). The immunizations were administered on Day 0 (primary), followed by two boosts on Days 29 and 54, 
respectively. Mice were tail-vein bled on Days 14, 46, and 84, followed by terminal bleed on Day 133. B. Antibody titers in sera from 
immunized BALB/c mice were determined by ELISA using lysate from lytically induced iSLK.219 KSHV-eGFP-expressing cells as target 
antigen. Serum samples from Days 14, 46, 84, and 133 diluted 1:100 in PBS were incubated in microtiter plates coated with iSLK.219 
KSHV-eGFP cell lysate. Lysates from iSLK cells (free of KSHV infection) and irrelevant ELL-0 cell lines were used as negative controls. 
Antibody binding was detected using HRP-labeled goat anti-mouse IgG secondary antibody. The absorbance resulting from serum antibody 
binding to KSHV-eGFP-expressing iSLK.219 cell lysate target antigen is shown as summary data for each group of mice. Absorbance data 
are shown as the mean (top of bar) ± the SEM (error bar above bar) for five mice per group (see Supplementary Figure 3 for individual mice 
at 2 time-point). KSHV VLPs induced increasing titers of anti-KSHV specific IgG antibodies after each immunization.
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titers peaked after the second boost immunization and did 
not significantly decrease until Day 133, suggesting that 
VLPs can induce long-term immunogenicity in mice. This 
also provides circumstantial evidence that memory plasma 
cells are developed in response to vaccination with KSHV 
glycoprotein-based VLPs.
UV-inactivated KSHV induced higher titers of 
KSHV-specific IgG antibodies than KSHV glycoprotein-
based VLPs administered singly or in combination, 
suggesting it was a better immunogen. However, the high 
antibody titers detected in response to UV-inactivated 
KSHV could be due to non-target-specific binding, 
possibly to UV-inactivated KSHV itself, or due to the 
presence of other antibodies directed to the iSLK.219 
cells used for virus production and as the target lysate 
in ELISA. Furthermore, whether some threshold level 
of vaccine-induced antibody titer is required to prevent 
infection in vivo remains to be elucidated in an appropriate 
animal model. A humanized mouse model [41] and non-
human primate model [42] have been developed and 
characterized to support studies of KSHV infection, and 
would be ideal for demonstrating in vivo efficacy of 
candidate vaccines in future studies. If increased antibody 
titers are required to prevent infection in vivo, we could 
increase immunogenicity by administering the KSHV 
glycoprotein-based VLPs in the presence of adjuvant 
[43], or by titrating the VLP concentration to achieve an 
optimal dose to elicit effective KSHV-specific neutralizing 
antibody titers [44].
Neutralizing antibodies can inhibit progression 
of herpesvirus-associated diseases [45–47]. Thus, a 
vaccine that elicits a neutralizing antibody response 
could help prevent KSHV infection and its associated 
malignancies in KSHV-endemic populations [48]. The 
KSHV glycoprotein-based VLPs induced neutralizing 
antibody responses in all immunized mice. The 
neutralizing antibodies blocked KSHV infection in vitro 
in a dose-dependent manner. Immunization with a single 
immunogen, gpK8.1, induced neutralizing antibody 
activity that was comparable to UV-inactivated KSHV, 
the gold standard. Immunization with a combination 
of gB and gH/gL VLPs induced a better neutralizing 
antibody response than either immunogen on its own. 
Importantly, combination of gpK8.1 with any other KSHV 
Figure 6: Neutralization assay of KSHV-eGFP with sera from mice immunized with KSHV VLPs. Pooled heat-inactivated 
terminal bleed sera from 5 animals per immunization treatment was pre-incubated with KSHV-eGFP purified from lytically induced 
iSLK.219 cells, then incubated at 37ºC for 2 h with HEK-293 cells. The virus/serum inoculum was removed and replaced with 10% 
DMEM, and the HEK-293 cells further incubated at 37ºC for 48 h. KSHV-eGFP+ cells, indicative of infection, were enumerated by 
flow cytometry. Known KSHV-positive plasma (488HO4; a gift of Dr. Wood University of Nebraska, Lincoln) and sera from UV-KSHV 
immunized mice served as positive controls Human sera 488HO4 neutralized ~80% of KSHV infection at 1:6, 1:9, and 1:18 dilutions. Sera 
from mice immunized with TNE (not shown) served as negative control and was used to normalize the percent infection. All the groups of 
mice immunized with single VLPs or different combinations of VLPs generated a neutralizing antibody response against KSHV-eGFP. At 
a 1:18 serum dilution, pooled serum from individual mice immunized with a combination of either gpK8.1-gH/gL, gB-gH/gL, or gpK8.1-
gB-gH/gL VLPs showed the best neutralization, inhibiting infection by 54.7%, 63.5%, and 51.0% respectively, compared to <50% for the 
mice immunized with single gpK8.1, gB, or gH/gL VLPs.
Oncotarget34491www.impactjournals.com/oncotarget
glycoprotein-based VLPs (gpK8.1-gB, gpK8.1-gH/gL, 
or gpK8.1-gB-gH/gL) induced a neutralizing antibody 
response that was comparable to that of UV-KSHV. This 
demonstrates the additive effect of combining more than 
one immunogen in a potential vaccine, and confirms 
that gpK8.1 is an important immunogen to include in 
the vaccine. We are currently developing a polyvalent 
VLP that expresses all four glycoproteins (gpK8.1, 
gB, and the gH/gL complex) on the surface of a single 
VLP. Multivalent VLPs are known to induce higher 
immunological responses than corresponding monovalent 
VLPs [49, 50]. A single, multivalent VLP would also be 
more cost-effective to produce in large-scale.
All herpesviruses persist for life in infected 
individuals, which means that only complete eradication 
of the latent virus can cure infection. Thus, our ultimate 
goal is to develop a vaccine that elicits both humoral 
and cellular responses to limit viral infection and 
eradicate infected cells. To elicit a cellular immune 
response in addition to the humoral response, future 
KSHV glycoprotein-based VLPs should also incorporate 
intracellular KSHV T-cell antigens, such as latent nuclear 
antigen-1 (LANA1; ORF73). LANA1 is responsible for 
maintaining KSHV as an episome in infected cells, while 
the virus undergoes latent replication [51]. LANA1 is 
expressed in all KSHV-infected cells, including KS tumor 
Figure 7: Neutralization assay of KSHV-eGFP+ with 1:9 diluted sera from mice immunized with KSHV VLPs. 
Neutralization assays were performed as described in Figure 6 and Materials and Methods. Data from three independent experiments at a 
1:9 serum dilution is presented. The percent inhibition of infection is shown as the mean (top of bar) ± the SEM (error bar above bar) for 
each serum group. Known KSHV positive plasma (488HO4) served as positive control and neutralized >80% of KSHV infection. Serum 
from mice immunized with TNE (data not shown) served as negative control and was used to normalize the percent infection. As a single 
immunogen, gpK8.1 VLPs stimulated comparable neutralizing antibody activity to that of UV-inactivated KSHV (positive control). In 
contrast, UV-inactivated KSHV stimulated higher titers of neutralizing antibodies compared to gB (p = 0.0316) or gH/gL (p = 0.0486). Mice 
immunized with the combination of gB and gH/gL VLPs had a better neutralizing antibody response than those immunized with either gB 
(p = 0.0268), or gH/gL (p = 0.0397) VLPs as single immunogens. Immunization with all VLP combinations containing gpK8.1 (gpK8.1-gB, 
gpK8.1-gH/gL and gpK8.1-gB-gH/gL) stimulated comparable neutralizing antibody activity to UV-KSHV serum.
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cells, and is a target of the cellular immune response 
mediated by CD4+ and CD8+ T cells [52]. LANA1-
specific T cells are effective in controlling growth of 
KSHV-immortalized endothelial and B cells [53, 54]. 
Therefore, we expect that a VLP comprised of gpK8.1-
gB-gH/gL and LANA1 would elicit both humoral and 
cell-mediated immune responses in immunized hosts. This 
dual response would allow the VLP vaccine to provide 
both a prophylactic and therapeutic effect; thus, it could be 
used to both prevent and treat KSHV and KS in endemic 
areas. The inclusion of other latent KSHV proteins, such 
as v-Cyclin (ORF72), v-FLIP (K13 or ORF71), Kaposin 
(K12), and viral miRNAs, which are also constitutively 
expressed from the latency locus of the viral genome 
[55], should be considered as part of a polyvalent KSHV 
vaccine. A polyvalent vaccine incorporating multiple 
KSHV glycoproteins and latent proteins could allow 
tailored targeting of KSHV-associated tumors as a 
therapeutic treatment strategy.
Study limitations
In vivo, KSHV typically infects epithelial, 
endothelial, and B cells [56]. Although we showed 
neutralization of infection in an epithelial cell model, due 
to limited amounts of mouse sera, we were unable to test 
the ability of the VLP-generated neutralizing antibodies 
to block virus infection in endothelial and B cells. Future 
studies could test this in primary cells or in cell lines 
susceptible to KSHV infection, such as MC116 [57].
CONCLUSIONS
We have generated the first KSHV subunit vaccines 
potentially capable of preventing KSHV infection in 
vivo and thus possibly capable of preventing KS. KS 
continues to be a major public health concern in sub-
Saharan Africa, where KSHV is endemic, and large 
numbers of HIV-infected individuals have late or no 
access to HAART [58]. A recent review on the burden 
of cancer associated with infectious agents listed KS as 
the second largest cancer burden in sub-Saharan Africa, 
behind only cervical cancer [59]. The accuracy of clinical 
and histopathologic diagnosis of KS in low-resource 
settings such as sub-Saharan Africa is sub-optimal [60]; 
thus, prevention is the best way to limit KS morbidity 
and mortality. A prophylactic vaccine to prevent KSHV 
and KS is critical to reduce the burden of disease in these 
settings. In endemic areas, KSHV infection is acquired 
mainly through horizontal transmission, most likely during 
childhood [4, 48]. A comprehensive prospective study 
evaluating and comparing primary infection with multiple 
herpesviruses in a cohort of African infants beginning 
at birth showed that despite endemicity of KSHV in the 
region, no KSHV infection was observed in the first 18 
months after birth [61]. Instead, other herpesviruses were 
acquired first. This evidence of delayed KSHV infection 
suggests that an 18-month window of opportunity 
exists, in which to vaccinate children and curb KSHV 
incidence and transmission. Furthermore, seroprevalence 
of KSHV is low in many developed countries; thus, an 
effective prophylactic vaccine will be an important tool 
in eradicating the rare cases of KS that occur during 
immunosuppression, especially in organ transplant or 
AIDS patients.
MATERIALS AND METHODS
Ethics statement
Animal procedures were performed in accordance 
with the University of Massachusetts Medical School 
(UMMS) Institutional Animal Care and Use Committee 
and Institutional Biosafety Committee.
Cell lines and virus
Chinese hamster ovary (CHO), human embryonic 
kidney (HEK-293), East Lansing Line 0 (ELL-0), and 
human mast (HMC-1) cell lines were purchased from the 
American Type Culture Collection (ATCC). Parent iSLK 
and iSLK.219 cells harboring KSHV expressing a reporter 
gene, enhanced green fluorescence protein, (eGFP), from 
the human elongation factor (EF)-1α promoter [62] were 
obtained from Dr. D. Dittmer of University of North 
Carolina, Chapel Hill, NC. CHO, HEK-293, and ELL-0 
cell lines were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM). HMC-1 cell line was cultured in 
Iscove’s Modified Dulbecco’s Medium. All cell culture 
media contained 10% heat-inactivated fetal bovine serum 
(FBS), 2% penicillin-streptomycin, and 1% L-glutamine. 
Media for culturing iSLK.219 cells was supplemented 
with neomycin (250 μg/mL), hygromycin (400 μg/mL), 
and puromycin (10 μg/mL) to maintain stable selection of 
both recombinant KSHV-eGFP and the RTA gene under 
the pRetro-X Tet-ON inducible system.
Lytic induction of KSHV-eGFP expression in 
iSLK.219 cells and KSHV-eGFP virus purification were 
performed as previously described [62]. Purified NDV 
B1 strain (lysate) was a gift of Dr. T. Morrison (UMMS, 
Worcester).
Antibodies and cholera toxin B
Primary mouse monoclonal IgG2a anti-gpK8.1 (clone 
4A4), which detects the ectodomain of the protein was 
purchased from Santa Cruz. Rabbit polyclonal anti-NDV 
and anti-NDV F HR2 have been described and were gifts 
of T. Morrison of UMMS, Worcester, MA [63]. Rabbit 
polyclonal anti-NDV F-tail was raised against a synthetic 
peptide (YKQKAQQKTLLWLGNN) with the sequence 
of the cytoplasmic domain of the fusion protein, (amino 
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acids 527 to 543) and purified by Thermo Scientific. 
Rabbit polyclonal anti-gB and anti-gH used in HMC-1 
cell binding experiments were gifts of Dr. B. Chandran of 
Rosalind Franklin University, Chicago, IL. KSHV-positive 
human plasma (488HO4) was obtained from Dr. C. Wood, 
University of Nebraska-Lincoln, NE [48]. Secondary 
antibodies horseradish peroxidase (HRP)-conjugated 
goat anti-mouse IgG and goat anti-rabbit IgG antibodies 
for immunoblot and ELISA were purchased from Sigma. 
Goat Fab-2 anti-mouse IgG (H+L) conjugated to AF488 or 
AF594, used for cytometric and fluorescence microscopy 
analyses, and molecular probe cholera toxin B conjugated 
with AF488, for staining lipid rafts, were all purchased 
from Thermo Scientific.
Plasmid vectors
Individual chimeric fragments consisting of 
amino acids (aa) 1-197, 1-736, and 1-702 encoding the 
gpK8.1, gB, and gH ectodomains, respectively, were 
constructed and fused to the NDV-F heptad repeat (HR2), 
transmembrane (TM), and cytoplasmic (CT) domains (aa 
466-553). A fragment encoding the TM and CT domains 
of the NDV-HN protein (aa 1-48) was fused to the 
ectodomain of gL (aa 29-167). The chimeric cDNAs were 
synthesized by Genewiz, Boston, MA, and individually 
cloned into the pCAGGS mammalian expression vector 
[64] to generate pCAGGS-KSHV gpK8.1-F, pCAGGS-
KSHV gB-F, pCAGGS-KSHV gH-F, and pCAGGS-
KSHV gL-HN. Full-length gpK8.1 wild-type (WT) (aa 
1-228), gB WT (aa 1-845), gH WT (aa 1-730), and gL WT 
(aa 1-167) were also synthesized and individually cloned 
into pCAGGS vector for use in control experiments. 
pCAGGS-F, pCAGGS-M, and pCAGGS-NP derived from 
NDV have been described [38]. All the cloned cDNAs 
were sequenced to confirm their fidelity.
gpK8.1 transfection and flow cytometry analyses
To determine surface expression of both wild-type 
and chimeric KSHV gpK8.1 envelope glycoprotein, 80% 
sub-confluent CHO cells seeded in six-well tissue culture 
plates were transfected with 1 µg/well of pCAGGS, 
pCAGGS-KSHV gpK8.1 full-length (WT), or pCAGGS-
KSHV gpK8.1-F using Mirus reagent (Mirus Bio LLC), 
according to the manufacturer’s instructions. Cells 
were harvested 48 h post-transfection, washed twice by 
centrifugation at 335 rcf for 5 min, and re-suspended in 
PBS. The cells were incubated with anti-gpK8.1 mAb for 
10 min at room temperature, washed twice, re-incubated 
with goat anti-mouse AF488, and washed thrice.
Cytometric analysis for gpK8.1 protein surface 
expression was performed on an LSRII benchtop FC 
(Becton-Dickinson, BD) and data was analyzed using 
Flow Jo Cytometry Analysis software (Tree Star Inc) as 
previously described [25]. A minimum of 10,000 events 
was recorded for each analysis. Experiments were repeated 
at least thrice and representative data is presented. Cell 
surface expression of gB-F, gB-WT, gH-F, gH-WT, gL-
HN, gL-WT, or gH-F/gL-HN were not determined by flow 
cytometry due to lack of primary monoclonal antibodies 
for staining transfected cells.
Generation and purification of VLPs
For VLP preparation, equal amounts (8 μg/plasmid) 
of pCAGGS-NDV-M, -NP, and either pCAGGS-KSHV 
gpK8.1-F, -gB-F, or -gH-F and -gL-HN (for KSHV 
gpK8.1, gB, and gH/gL VLPs, respectively) were co-
transfected into CHO cells seeded in T-175 cm2 flasks, 
using Mirus reagent, as previously described [25]. Forty 
flasks were seeded for each VLP preparation. Supernatant 
containing VLPs was collected between 24 to 96 h post-
transfection. VLPs were isolated by sedimentation and 
sucrose gradient purification, as previously described [36].
Silver stain and immunoblot
To detect the incorporation of proteins into VLPs, 
purified KSHV glycoprotein-based VLPs, untransfected 
CHO cells (negative control), and cells transfected with 
the respective wild-type proteins (positive controls) 
were first lysed in RIPA buffer (Boston Bioproducts). 
Lysates were incubated on ice for 30 min, with vortexing 
every 10 min, then centrifuged for 10 min at 18,407 rcf 
in a microcentrifuge. The protein content of each lysate 
was determined by Bradford assay (Sigma). Lysates 
were boiled for 5 min in lithium dodecyl sulphate 
sample buffer (Thermo Scientific) under reducing and 
non-reducing conditions. A known quantity of protein 
lysate was loaded onto a 4–12% polyacrylamide gel for 
protein separation using 1X MES SDS running buffer 
(Life Sciences Technologies). Immunoblot analyses for 
respective proteins (gpK8.1, gB, gH/gL, NDV-NP, and 
-M) were performed by transferring proteins from the gel 
to a polyvinylidene fluoride membrane using iBlot (Life 
Sciences Tech). Membranes were blocked with 3% bovine 
serum albumin (Sigma) in Tris-buffered saline (TBS) for 
45 min and proteins were detected with specific primary 
and secondary antibodies as previously described [65, 66]. 
Protein bands were also detected by Pierce’s silver stain 
kit according to the manufacturer’s recommendation.
Cell binding assays and electron microscopy
VLPs and viruses were analyzed by electron 
microscopy as described [67]. For cell binding assays, 5 
µl of KSHV glycoprotein-based purified VLPs (gpK8.1, 
gB, or gH/gL) were incubated with HMC-1 cells for 
10 min at room temperature and detected with anti-
gpK8.1 mAb, polyclonal anti-gB, or polyclonal anti-
gH. Lipid rafts in the cell membranes were stained with 
cholera toxin (cell membrane tracker) and nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI). For 
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electron microscopy, purified VLPs were dialyzed against 
1 L of TNE buffer (100 mM Tris; 2.0 M NaCl; 10 mM 
EDTA; pH 7.4) to remove residual sucrose, incubated 
with 3% bovine serum albumin (BSA) in TNE for 45 
min, and embedded on a grid. 5 µl of the virus/VLP at 
1:40 dilution was individually added to the grid for 1 h at 
room temperature. After two final washes, the grids were 
negatively stained with 12% phosphotungstic acid (pH 7) 
for 15 sec, air dried for 30 min, and examined using a 
Tecnai transmission electron microscope (FEI).
Immunization
Nine groups of five 6–8-week-old female BALB/c 
mice (Jackson Laboratories) each were immunized 
intraperitoneally with 10 µg of either purified KSHV gpK8.1 
VLP, gB VLP, gH/gL VLP, or combinations of gpK8.1 and 
gB, gpK8.1 and gH/gL, gB and gH/gL, or gpK8.1 and gB 
and gH/gL VLPs in 0.5 mL TNE buffer containing ~10% 
sucrose without any adjuvant. UV-inactivated KSHV-eGFP 
purified from lytically induced iSLK.219 cells (10 µg in 0.5 
mL TNE) or TNE buffer alone (0.5 mL) served as positive 
and negative controls, respectively. UV-inactivation of 
KSHV was achieved by exposure to 254 nm UV light for 
5 min (source model UVG-11, UVP) from a distance of 
10 cm, producing complete loss of eGFP expression upon 
KSHV infection of 293T cells.
Mice were boosted with 10 µg of each antigen on 
Days 29 and 54. After primary immunization, tail vein 
blood was obtained at Days 14, 46, and 84. A terminal 
bleed was obtained on Days 133. All time points were 
used to determine anti-KSHV glycoprotein IgG response.
Enzyme-linked immunosorbent assay (ELISA) 
to determine sera antibody titer
Anti-KSHV IgG absorbance was measured by 
ELISA using cell lysate from iSLK.219 cells stimulated to 
induce lytic expression of KSHV-eGFP proteins as a target 
antigen. Lysates from iSLK cells (free of KSHV infection) 
and irrelevant ELL-0 cell lines were used as negative 
controls. Briefly, 96-well microtiter plates (Costar) were 
coated overnight with 8 µg/mL per well of lytically induced 
iSLK.219 KSHV-eGFP-expressing cell lysate in PBS 
at 4°C, then blocked with 2% BSA at room temperature. 
Serum samples diluted 1:100, 1:300, 1:900, and 1:2700 in 
PBS were added, incubated for 2 h at room temperature, 
then washed thrice. Antibody binding was detected with 
HRP-labeled goat anti-mouse IgG secondary antibody 
incubated at room temperature for an hour. Plates were 
washed five times and the substrate ABTS (KPL) was 
added. Reactions were stopped with ABTS peroxidase stop 
solution (KPL). Optical density (OD) was read at 450 nm 
with an ELISA reader (FilterMax F3) and corrected for 
background. The absorbance resulting from serum antibody 
binding to KSHV-eGFP-expressing iSLK.219 cell lysate 
target antigen is shown as summary data for each group of 
mice. Absorbance data at 1:100 are provided as the mean 
(top of bar) ± the SEM (error bar above bar) for five mice 
per group. KSHV VLPs induced increasing titers of anti-
KSHV specific IgG antibodies after each immunization.
KSHV neutralization studies
Terminal bleed sera from each group of immunized 
mice were pooled and incubated at 56°C for 30 min to 
heat-inactivate serum complement. The virus titer for the 
in vitro neutralization assays was determined as described 
[25]. Briefly, different concentrations of a frozen stock of 
KSHV-eGFP purified from lytically induced iSLK.219 
cells were incubated with HEK-293 cells seeded overnight 
in 48-well plates, in the absence of serum. Flow cytometry 
was used to detect fluorescence, indicative of infection. 
After infection with 30 μl of stock KSHV-eGFP, ~15% 
(1,500 cells) of total seeded HEK-293 cells reproducibly 
fluoresced upon detection by flow cytometry. For effective 
flow cytometry reading, the number of HEK-293 cells 
was increased and seeded in 24-well plates and the 
amount of virus used for infection was doubled to 60 μl to 
accommodate the increase in cell population.
Serial two-fold dilutions of heat-inactivated sera 
were prepared in Dulbecco’s modified Eagle’s medium 
(DMEM) without fetal bovine serum to a volume of 60 μl. 
This serum was incubated with 60 μl KSHV-eGFP for 2 h at 
37°C. The serum/virus mixture was topped up with serum-
free media to a final volume of 200 μl, yielding dilutions 
ranging from 1:3 to 1:150, then used to infect HEK-293 
cells that had been seeded at 60-80% confluence in 24-
well plates the night before. The KSHV-eGFP-incubated 
sera were cultured with the cells for 2 h at 37°C. Known 
neutralizing KSHV-positive plasma (488HO4) [48] and 
serum from TNE only-treated mice served as positive and 
negative controls, respectively. The virus/serum inoculum 
was removed and replaced with 500 μl of fresh DMEM 
plus 10% FBS. Plates were incubated for 48 h at 37°C 
and the number of eGFP-positive cells was determined 
by flow cytometry. Neutralization assays were performed 
in triplicate to determine the optimal serum dilutions for 
the assays. Evaluation of data to determine the magnitude 
of neutralization was performed as previously described, 
and quantified as percent inhibition of viral infection [48]. 
Briefly, sample data was first normalized to input viral 
infection and calculated as: Normalized Percent Infectivity 
= (Sample percent infectivity/Virus-only percent infectivity) 
x 100. The percent inhibition of viral infection was then 
calculated as: (100 - Normalized Percent Infectivity).
Statistical analysis
Graph Pad Prism 6 Software was used for statistical 
analyses of data. The differences between the percent 
inhibition of infection between the immunized and control 
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groups of mice were analyzed using unpaired two-tailed 
t-tests for independent groups. Statistical significance 
of the tests was based on a p-value equal to or lower 
than 0.05.
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